Technology ID
TAB-4868
Monoclonal Antibodies Targeting Bacillus anthracis Lethal Factor: Potential Tools for Anthrax Detection and Intervention
E-Numbers
E-047-2018-0
Lead Inventor
Leppla, Stephen
Lead IC
NIAID
ICs
NIAID
Applications
Therapeutics
Diagnostics
Therapeutic Areas
Infectious Disease
Development Stages
Analytical Assay Performance Stage
Research Products
Antibodies
The technology involves the development of monoclonal antibodies produced by hybridomas, including cell lines such as 10G3, 3E6, 10D4, 10G4, 1D8, 13D10, 9E5, and 9F10, which specifically react with Bacillus anthracis Lethal Factor (LF). These monoclonal antibodies offer valuable applications in anthrax detection, therapeutic intervention, and research into the biology of Bacillus anthracis and its lethal toxin. This advancement provides promising tools for mitigating the impact of anthrax infections and advancing our understanding of this deadly pathogen.
Commercial Applications
These monoclonal antibodies have diverse applications. They can be used in accurate anthrax detection, rapid response to outbreaks, and therapeutic development. In research, they deepen our understanding of Bacillus anthracis. Their versatility makes them valuable in biodefense, public health, and scientific exploration.
Competitive Advantages
Monoclonal antibodies targeting Bacillus anthracis Lethal Factor (LF) offer a precise and versatile solution for anthrax detection, intervention, and research. Their specificity and established reliability make them a competitive asset in various applications, from diagnostics to therapeutics.
Licensing Contact: